R&D Investment by U.S. Biopharma Firms Reached Record Levels in 2010

Among PhRMA member companies, more than 75 percent of research dollars were invested in the U.S.

America’s biopharmaceutical research companies invested a record $67.4 billion last year in the research and development of new medicines and vaccines – an increase of $1.5 billion from 2009, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company.

PhRMA member companies alone spent an estimated $49.4 billion on biopharmaceutical R&D last year, a 6.5 percent increase over 2009, according to the PhRMA survey. The Burrill & Company analysis shows that additional biopharmaceutical research companies in the United States spent an estimated $18.0 billion on R&D in 2009.

America’s biopharmaceutical research companies lead the world in the pursuit of new, life-saving and life-enhancing m